Ziihera can now be used as an initial treatment for all HER2-positive gastroesophageal adenocarcinomas, dramatically expanding the drug’s market potential.
An article from
Dive Brief
Ziihera can now be used as an initial treatment for all HER2-positive gastroesophageal adenocarcinomas, dramatically expanding the drug’s market potential.
Published Aug. 25, 2026
The FDA on Aug. 25, 2026 expanded use of Ziihera, a drug discovered by Zymeworks and jointly sold by Jazz Pharmaceuticals and BeOne Medicines.
Jazz Pharmaceuticals’ bispecific antibody Ziihera has gained FDA approval for first-line HER2-positive stomach cancer, unlocking…
Jazz's Ziihera wins FDA nod for frontline HER2+ gastric cancer, clearing use with chemo, with or without BeOne's Tevimbra.
The FDA approved two zanidatamab-hrii-based regimens as first-line treatment for adults with unresectable locally advanced or…
FDA approves Jazz Pharmaceuticals' Ziihera combinations for first-line treatment of HER2-positive gastroesophageal adenocarcinoma.
FDA approves JAZZ's Ziihera-containing combination regimens for HER2-positive gastroesophageal adenocarcinoma. JAZZ stock drops…
Also known as Ziihera, the antibody treatment targets a protein called HER2, which stimulates tumour growth. It works by…
